Insider trading

Period: 120 months Stock: PTGX Share of holding: 50% or more × + Add filter Clear all
Views & alerts

Save your view. Keep the filter you have built, and get an email when a new filing matches it. A free account does both.

When

Period

How far back the list reaches. Filings arrive days after the trade, so the newest rows always lag a little.

22 decisions over 120 months
Who

Role

The position the person holds at the company, read from the title on the filing. A chief executive who is also a director counts as the chief executive.

22 decisions over 120 months
The trade

Type of trade

Purchases, sales, or cluster buys: companies where 3 or more insiders bought within 30 days. The number beside each is what that choice would give.

22 decisions over 120 months
The trade

Minimum amount

Hides rows under this value. The amount is the shares traded times the price on the filing.

22 decisions over 120 months
The trade

Plan

  • Discretionary: they chose to sell that week.
  • Scheduled: a 10b5-1 plan fixed the sale months in advance, so the timing says nothing about what they knew.
  • Not stated: filed before the SEC added the box in April 2023, which is most of the older half of this database.
22 decisions over 120 months
The trade

Share of their own holding

How much of what they already held the trade moved. Selling a tenth of a stake is not the same act as selling all of it.

At least
22 decisions over 120 months Remove this filter
Ownership

What the chief executive holds

The value of the chief executive’s stock measured against base salary. The salary comes from the company’s own proxy. Companies with no figure are in neither direction.

22 decisions over 120 months
Stock
Insider
Type ?
Why it stands out
23 Jun 2026
Sold on a plan
$1.06M 9,000 at 117.94
53.5%
Sold half or more
10 Jun 2026
Sold on a plan
$969.12K 9,000 at 107.68
53.5%
Sold half or more
29 May 2026
Sold on a plan
$896.76K 9,000 at 99.64
53.5%
Sold half or more
8 May 2026
Giraudo Bryan Director · indirect
Sold at will
$600.00K 6,000 at 100.00
100%
Sold half or more
7 May 2026
Giraudo Bryan Director
Sold at will
$3.61M 36,000 at 100.14
56.4%
Sold half or more
7 May 2026
Giraudo Bryan Director · indirect
Sold at will
$1.20M 12,000 at 100.07
66.7%
Sold half or more
17 Feb 2026
Williams Lewis T Director
Sold at will
$1.48M 18,000 at 82.42
69.7%
Sold half or more
6 Feb 2026
Sold at will
$1.67M 20,000 at 83.68
71.9%
Sold half or more
10 Oct 2025
Sold on a plan 2×
$979.48K 12,000 at 81.62
70.1%
Sold half or more
1 Mar 2024
Sold on a plan
$406.64K 12,975 at 31.34
52.0%
Sold half or more
11 Feb 2021
Sold, plan not stated
$92.83K 3,700 at 25.09
100%
Sold half or more
10 Feb 2021
Sold, plan not stated 2×
$119.72K 4,700 at 25.47
100%
Sold half or more
11 Aug 2020
Sold, plan not stated
$42.95K 2,499 at 17.19
100%
Sold half or more
12 Mar 2020
SELICK HAROLD E Director
Bought
$80.40K 12,000 at 6.70
363%
First buy on file
3 Dec 2019
Gupta Suneel EVP Clinical Operations
Bought
$153.90K 30,000 at 5.13
154%
First buy on file
22 Dec 2017
Shames Richard S. Chief Medical Officer
Sold, plan not stated
$72.34K 3,529 at 20.50
100%
Sold half or more
18 Dec 2017
O'Neil Thomas P. Chief Financial Officer
Sold, plan not stated
$160.00K 8,000 at 20.00
100%
Sold half or more
13 Nov 2017
Liu David Y Chief Scientific Officer
Sold, plan not stated 2×
$118.76K 7,000 at 16.97
64.7%
Sold half or more
5 Oct 2017
Shames Richard S. Chief Medical Officer
Sold, plan not stated
$38.32K 2,017 at 19.00
100%
Sold half or more
12 Sep 2017
Shames Richard S. Chief Medical Officer
Sold, plan not stated
$52.75K 3,687 at 14.31
100%
Sold half or more
28 Aug 2017
Liu David Y Chief Scientific Officer
Sold, plan not stated
$52.50K 3,500 at 15.00
63.6%
Sold half or more
10 Jul 2017
Liu David Y Chief Scientific Officer
Sold, plan not stated
$44.38K 3,500 at 12.68
63.6%
Sold half or more
Showing 1–22 of 22.